Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 September;55(3) > Panminerva Medica 2013 September;55(3):283-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Panminerva Medica 2013 September;55(3):283-9

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Overexpression of stearoyl-CoA desaturase 1 in bone-marrow mesenchymal stem cells increases osteogenesis

Tao J. 1, Shi J. 2, Lu Y. 3, Dou B. 1, Zhou Z. 1, Gao M. 1, Zhu Z. 4

1 Department of Orthopedics Shanghai First People’s Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China; 2 The First Clinical Medical College Nanjing Medical University, Nanjing, China; 3 Department of Blood Supply Shanghai First People’s Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China; 4 Department of Orthopedics Shanghai Ninth People’s Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China


PDF


Aim: The goal of this study was to examine the relationship between stearoyl-CoA desaturase 1 (SCD1) and osteogenesis in bone marrow mesenchymal stem cells (BM-MSCs).
Methods: SCD1 was overexpressed in BM-MSCs using lentiviral transduction. Then, osteogenesis was induced by low glucose DMEM (10% fetal bovine serum). Alkaline phosphatase (ALP) activity assays, Western blot analyses of SCD1 and osteocalcin, and stainings for ALP and alizarin red were done to assess the extent of osteogenesis in BM-MSCs.
Results: ALP activity was markedly higher in the SCD1 overexpressing cells compared with cells transduced with empty vector or control (untransduced) cells at 1 and 2 weeks after osteogenic induction. By contrast, ALP activities were comparable between control cells and cells transduced with empty vector. Western blot analysis demonstrated that osteocalcin levels were higher in the SCD1 overexpressing cells, compared with cells transduced with empty vector or control cells, at 1 and 2 weeks after osteogenic induction. These findings were corroborated by stainings for ALP and alizarin red that demonstrated a more active osteogenesis in the SCD1 overexpressing cells 2 weeks after osteogenic induction.
Conclusion: Increased levels of SCD1 enhance osteogenesis in BM-MSCs.

top of page